PharmaTher Holdings Unveils Personaliz3D Peptides™ Division Leveraging 3D Printing and AI After Favorable FDA Advisory Committee Recommendations

Overcoming Challenges in Peptide Care and Compounding

PharmaTher highlights significant challenges in current peptide therapy delivery, such as limited dosage flexibility, inconvenient administration methods, concerns about peptide quality and consistency, and lack of personalized formulations tailored to individual patient needs. Healthcare providers and pharmacies also face a shortage of integrated technology platforms, validated formulations, and scalable production systems for customized peptides.

The traditional peptide compounding approach is marked by fixed dosing, injectable or liquid-only formulations, and fragmented access involving separate prescribers, pharmacies, and technology providers. This fragmentation leads to variability in quality standards and restricted access to verified GMP-compliant manufacturing controls. Personaliz3D Peptides™ aims to address these market deficiencies.

Innovative Technology Integration: 3D Printing and AI

The Personaliz3D Peptides™ division will combine 3D printing and AI technologies with physician oversight, telemedicine services, qualified compounding pharmacies, proprietary formulations, and precise dosing capabilities. These innovations are expected to enable advanced, individualized treatment designs, including alternative delivery formats beyond traditional injections and liquids.

Potential delivery formats include gummies, oral films, tablets, gels, chews, suppositories, and patches. AI will assist in optimizing formulations, protocols, and patient-specific treatment plans, while 3D printing will allow qualified providers to produce customized formulations based on specific dosing, combinations, and release profiles. All production will adhere to GMP standards and include Certificates of Analysis for quality assurance.

FDA PCAC Recommendations and Regulatory Outlook

PharmaTher’s announcement references favorable votes by the FDA’s Pharmacy Compounding Advisory Committee on six peptide bulk substances: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. The PCAC recommended adding these to the Section 503A Bulks List, which PharmaTher views as a key step toward a responsible regulatory framework for personalized peptide medicines in the U.S.

The company cautions that the PCAC’s recommendation is advisory and non-binding, not constituting FDA approval or authorization for compounding under Section 503A. Compounded drugs are not FDA-approved or evaluated for safety, effectiveness, or quality, and all related activities will comply with applicable laws and regulations. The regulatory pathway remains uncertain and subject to future FDA decisions and rulemaking.

Strategic Framework: Connect, Personalize, Deliver

PharmaTher outlines a three-part strategy for the Personaliz3D Peptides™ ecosystem. "Connect" involves developing the PersonalizedPeptidesRx.com telemedicine platform to link eligible patients with qualified healthcare providers for assessment and ongoing oversight.

"Personalize" focuses on leveraging 3D printing and AI-assisted technologies to create proprietary peptide formulations, protocols, and dosage formats for qualified providers including 503A compounding pharmacies, physicians, clinics, and licensed practitioners. Personalization features under development include patient-specific dosing, micro-dosing, combination peptides, various release profiles, and alternative delivery formats.

"Deliver" entails forming partnerships with qualified 503A compounding pharmacies, healthcare providers, researchers, technology firms, and pharmaceutical companies to support compliant development, preparation, and delivery of personalized peptide therapies.

Telemedicine Platform and Development Timeline

Launching the PersonalizedPeptidesRx.com telemedicine platform is a top priority for the division. While currently under development, no specific launch date has been disclosed. This platform will serve as the central hub connecting patients, providers, and compounding pharmacies.

Additional initial priorities include developing proprietary formulations and protocols, creating non-invasive dosage forms, advancing precise dosing and combination products, establishing collaborations with 503A pharmacies and healthcare providers, developing training and certification programs, integrating pharmacy and physician data systems, and securing intellectual property related to production methods, formulations, protocols, software, and personalized medicine technologies.

Commercial Model and Partnership Strategy

PharmaTher plans a partnership-driven commercialization approach for Personaliz3D Peptides™ to support independent healthcare providers and pharmacies while generating diverse revenue streams and intellectual property opportunities. The company identifies eight potential revenue channels: personalized peptide therapies via telemedicine; 3D printing systems and services; telemedicine and pharmacy platform participation; licensing proprietary formulations, protocols, software, and AI tools; consumables and manufacturing materials; formulation development and small-batch manufacturing; training, certification, and onboarding; and sales, royalties, and milestone payments from proprietary or partnered products.

PharmaTher is building an integrated network of qualified pharmacy, healthcare, technology, and supply partners to support product development, GMP-compliant manufacturing, data integration, and future personalized peptide delivery. This model enables independent pharmacies and providers to participate in a comprehensive personalized peptide platform while maintaining their professional, regulatory, and patient-care responsibilities.

Focus on Intellectual Property and Proprietary Innovation

Intellectual property development is a core strategic focus for Personaliz3D Peptides™. The company is pursuing IP protection for production methods, formulations, protocols, software, and personalized medicine technologies. Licensing opportunities for proprietary assets are integral to the division’s long-term commercial strategy.

PharmaTher aims to establish competitive advantages through proprietary 3D printing recipes, formulation data, treatment protocols, and software platforms. The integration of AI-assisted technologies may further enhance patent protection and licensing potential with partners.

Regulatory and Operational Considerations

The announcement acknowledges regulatory and operational constraints governing Personaliz3D Peptides™ activities. All operations will comply with applicable laws and regulations. Material risks include potential non-acceptance of PCAC recommendations by the FDA, evolving regulatory requirements, and possible restrictions on peptide bulk substances.

Additional risks involve challenges in developing, launching, or gaining adoption for PersonalizedPeptidesRx.com; validating and commercializing 3D printing technologies; successfully establishing the division; and protecting or commercializing proprietary formulations, protocols, and personalized peptide products. These statements underscore the uncertainties inherent in the division’s planned initiatives.

Company Overview and Strategic Expansion

PharmaTher Holdings Ltd. is a specialty pharmaceutical company focused on personalized medicines, particularly peptides and psychedelics. The launch of Personaliz3D Peptides™ marks a significant expansion and specialization of its peptide-focused operations. The announcement does not disclose current financials or operating history related to existing business segments.

Chairman and CEO Fabio Chianelli emphasized the company’s vision, stating, "Patients and healthcare providers should not have to rely on a one-size-fits-all approach when individual treatment needs can differ significantly." This underscores the strategic rationale for the new division and its positioning within the personalized medicine landscape.